602 related articles for article (PubMed ID: 26959143)
1. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
Eldweik L; Mantagos IS
Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
3. [VEGF antibodies as therapy for retinopathy of prematurity].
Oberacher-Velten IM; Helbig H
Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
[TBL] [Abstract][Full Text] [Related]
5. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II.
Autrata R; Krejcírová I; Senková K; Holoušová M; Doležel Z; Borek I
Eur J Ophthalmol; 2012; 22(5):687-94. PubMed ID: 22669848
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity.
Ehmann D; Greve M
Can J Ophthalmol; 2014 Apr; 49(2):228-31. PubMed ID: 24767234
[TBL] [Abstract][Full Text] [Related]
9. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF).
Tsai AS; Chou HD; Ling XC; Al-Khaled T; Valikodath N; Cole E; Yap VL; Chiang MF; Chan RVP; Wu WC
Prog Retin Eye Res; 2022 May; 88():101018. PubMed ID: 34763060
[TBL] [Abstract][Full Text] [Related]
10. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal anti-VEGF treatment for retinopathy of prematurity in infants with active adenoviral keratoconjunctivitis.
Koçluk Y; Alyamaç Sukgen E
Cutan Ocul Toxicol; 2018 Mar; 37(1):15-18. PubMed ID: 28393562
[TBL] [Abstract][Full Text] [Related]
13. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.
Mititelu M; Chaudhary KM; Lieberman RM
J Pediatr Ophthalmol Strabismus; 2012; 49(6):332-40. PubMed ID: 22938516
[TBL] [Abstract][Full Text] [Related]
14. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy.
Tran KD; Cernichiaro-Espinosa LA; Berrocal AM
Asia Pac J Ophthalmol (Phila); 2018; 7(1):56-62. PubMed ID: 29376233
[TBL] [Abstract][Full Text] [Related]
15. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic therapy in the management of retinopathy of prematurity.
Drenser KA
Dev Ophthalmol; 2009; 44():89-97. PubMed ID: 19494656
[TBL] [Abstract][Full Text] [Related]
17. [Retinopathy of prematurity - therapy. Part 2].
Prepiaková Z; Tomčíková D; Kostolná B; Gerinec A
Cesk Slov Oftalmol; 2014 Apr; 70(2):50-4. PubMed ID: 25030312
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
[TBL] [Abstract][Full Text] [Related]
19. Current and future trends in treatment of severe retinopathy of prematurity.
Wallace DK; Wu KY
Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
[TBL] [Abstract][Full Text] [Related]
20. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
[No Abstract] [Full Text] [Related]
[Next] [New Search]
